Pyrazinamide

C. diff Risk

Low

Oral Bioavailability

Moderate

Approximate Cost

$

Spectrum Of Activity

Dosing

40 to 55 kg56 to 75 kg76 to 90 kg1,000 mg once daily1,500 mg once daily2,000 mg once daily

Altnerate options available, including 3 times weekly therapy. Consult ID.

Use ideal body weight for dosing

CrCl >50 mL/minCrCl <30 ml/minDialysis (HD)Dialysis (CRRT)20 - 25 mg/kg/day PO Q24h25-35 mg/kg 3x/week25-35 mg/kg three 3x/week Post HD25-35 mg/kg 3x/week

  •  No dosage adjustments.

  •  Use is contraindicated in cases of severe hepatic impairment.

General Information

  •  Malaise

  •  Anorexia

  •  Nausea

  •  Vomiting

  •  Arthralgia

  • Myalgia

  • Hepatotoxicity

Laboratory

  •  CBC with diff and CMP at start and periodically during course

Clinical

  • Monitor for hepatotoxicity

Cyclosporine, rifampin, multiple additional

Caution in:

  • Alcoholism

  • Diabetes

  • Gout

  • Porphyria

  • Renal impairment

Metabolism: Hepatic

Active Tuberculosis treatment